Latest Uric acid Stories
The incidence of gout is on the rise and duel energy CT has the potential to allow non-invasive diagnosis of the disease.
EAST BRUNSWICK, N.J., April 28, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that three abstracts will be presented at the European League Against Rheumatism (EULAR) 2011 Annual Congress.
SAN DIEGO, April 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc.
SAN DIEGO, April 6, 2011 /PRNewswire/ -- Getting the word out about preventing and treating gouty arthritis has new urgency with the number of Americans suffering from this form of arthritis now topping the 8 million mark. If left untreated, gout can be disabling.
TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints.
The amount of uric acid in one's joints may increase the likelihood of severe osteoarthritis, the most common form of arthritis worldwide.
SAN DIEGO, Jan. 6, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol.
BURLINGTON, Mass., Dec.
EXTON, Pa., Dec. 8, 2010 /PRNewswire/ -- BioTrends Research Group, Inc.
EAST BRUNSWICK, N.J., Nov. 30, 2010 /PRNewswire/ -- Savient Pharmaceuticals, Inc.
- An interdisciplinary study of social injustice.